IPM Take
Insurance has traditionally asked a simple question about health:
How much risk does this person represent?
The emerging metabolic-health model asks something more disruptive:
Can the insurer change that risk after the policy begins?
At LIMRA’s 2026 Annual Conference, executives and clinicians argued that obesity, type 2 diabetes and insulin resistance should not be treated only as variables in underwriting models. They proposed using nutrition support, health coaching, biomarker monitoring and, where appropriate, medicines such as GLP-1 therapies to improve policyholder health and potentially reduce future claims.
That is potentially attractive for everyone involved.
A policyholder becomes healthier. An insurer pays fewer disability or mortality claims. People previously considered more difficult to insure might eventually become easier to cover.
But the logic only works if the interventions actually produce durable health improvements and if the financial benefits are demonstrated rather than assumed.
And there is a second problem.
The closer insurers move toward managing health, the more information they may have about the people they insure. That makes questions about consent, data governance, underwriting fairness and the separation between helping people reduce risk and using health data to reclassify risk increasingly difficult to avoid.
Executive Summary
A panel at the 2026 LIMRA Annual Conference in Texas framed metabolic health as an emerging business strategy for life insurers. Participants included representatives from Swiss Re, Virta Health and the Insurance Collaboration to Save Lives. The discussion focused on whether insurers could move beyond measuring and pricing metabolic risk toward helping policyholders reduce it through lifestyle intervention, clinical support and medication where appropriate.
Swiss Re has already tested this idea in a UK disability-insurance pilot. The programme embedded nutrition-focused metabolic-health support within claims management and offered eligible claimants either residential or virtual intervention alongside clinical and vocational support. Swiss Re reports that five participants returned to work, releasing more than £790,000 in claims reserves, against a total programme cost of approximately £32,000.
Those results are commercially striking but preliminary. The pilot was small, not randomised and designed as a claims-management intervention rather than a controlled health-economic study. It cannot establish that the same return would be reproduced across broader insured populations.
Swiss Re is also studying GLP-1 use from an underwriting perspective. Its 2026 analysis of US insurance-applicant data found rapidly increasing GLP-1 use and an association between stronger medication adherence and lower modelled mortality risk. Importantly, treatment duration itself was not independently associated with lower modelled risk, leading the authors to emphasise underlying disease, adherence and sustained behavioural change.
Why it matters
- HTA bodies: Life-insurance interventions sit largely outside conventional HTA, but the underlying issue is familiar: a programme should not be judged only by biomarker improvement or weight loss. Claims reduction, sustained health benefit, return to work, quality of life and long-term outcomes need credible comparative evidence.
- → Payers: Insurers have a direct financial incentive to prevent costly disease progression. If metabolic programmes reliably reduce disability, hospitalisation or premature mortality, private payers may become increasingly willing to finance prevention earlier. The risk is that programmes are targeted primarily where a business case is strongest rather than where population-health need is greatest.
- → Industry / innovation partners: Insurers could become a new customer for metabolic-health platforms, remote care, GLP-1 support services and biomarker monitoring. But products will need to demonstrate durable outcomes and measurable return on investment, not simply engagement or short-term weight reduction.
Life insurance has always been in the business of predicting health.
It may be edging toward something more ambitious: trying to improve it.
At the LIMRA Annual Conference in Texas, a session titled “Metabolic Health as a Business Strategy: From GLP-1s to Portfolio Value” brought together insurers and clinical-service providers to discuss whether metabolic disease could become an intervention target rather than simply an underwriting variable.
The premise is straightforward.
Obesity, diabetes, cardiovascular disease and fatty liver disease cluster together, and many of the same patients accumulate several conditions over time. Those illnesses can increase mortality risk, disability, healthcare use and ultimately insurance claims.
Traditionally, insurers have responded by trying to measure that risk accurately.
Panelists suggested another option: reduce it.
From underwriting to intervention
Swiss Re chief medical officer John Schoonbee told the LIMRA audience that insurers could play a more active role in improving metabolic health rather than limiting themselves to risk assessment. GLP-1 drugs were part of that discussion, alongside nutrition and lifestyle interventions.
The change sounds subtle, but it alters the insurance model.
Underwriting is largely predictive. It asks about the probability of a future event.
A metabolic-health programme is interventional. It attempts to change that probability.
Swiss Re has already tested the concept in UK disability insurance.
The reinsurer says an internal analysis found that metabolic dysfunction was common among long-term disability claimants. It then partnered with external providers on a nutrition-focused programme integrated directly into claims management.
Eligible claimants received either a residential intervention or a 12-week virtual programme involving coaches, dietitians, clinical oversight and vocational rehabilitation, followed by longer-term support.
Swiss Re reports that five participants returned to work and that this released more than £790,000 in claims reserves, while the programme cost approximately £32,000 across participants.
Those numbers make a compelling case for further testing.
They do not yet make a population-level business case.
The intervention was a targeted pilot involving selected disability claimants, and the published Swiss Re account does not provide the kind of randomised comparator needed to establish how much of the return-to-work effect was caused by the metabolic programme itself.
That distinction is essential if insurers begin using similar figures to justify wider roll-out.
GLP-1s complicate the calculation
The arrival of GLP-1-based therapies makes the insurance question more interesting.
These drugs can produce substantial weight loss and improve cardiometabolic outcomes in appropriate patients, potentially changing the long-term risk profile of people who historically would have been viewed as higher-risk insurance applicants.
But insurers do not yet know exactly how that translates into decades of mortality and claims experience.
Swiss Re’s April 2026 analysis of US applicant data found that GLP-1 use had increased fivefold since 2020. Nearly one third of GLP-1 users in its 2025 dataset did not have a diabetes prescription code.
GLP-1 users still had higher average modelled mortality risk than the overall applicant population, largely reflecting the underlying metabolic conditions for which they were being treated.
More interestingly, higher medication adherence was associated with lower modelled mortality risk, while simply being on treatment for longer was not independently associated with lower risk.
That is an important warning against simplistic underwriting.
A prescription does not automatically convert a high-risk applicant into a low-risk one.
Nor does a lower body weight necessarily capture the full trajectory of metabolic disease.
Could better health expand access to insurance?
The most provocative idea raised at LIMRA was that intervention could eventually affect insurability itself.
Panelists suggested that people who struggle to obtain traditional coverage because of poor health might participate in health-improvement programmes, potentially creating a pathway toward coverage that would otherwise be difficult to secure.
That could expand protection.
But it also creates a sensitive policy question.
Would metabolic-health support become an opportunity offered to people considered high risk, or an expectation attached to access, pricing or continued eligibility?
Those are very different models.
A voluntary programme that helps an existing policyholder manage diabetes is one thing.
A system in which access to favourable premiums becomes increasingly tied to participation, biomarker improvement or continuous health monitoring is another.
Better data can improve risk assessment, but also sharpen its edges
The US regulatory debate around life-insurance underwriting already reflects some of these tensions.
The National Association of Insurance Commissioners notes that life insurers increasingly use external data, predictive models and accelerated underwriting systems. Its guidance emphasises actuarial justification, transparency and testing for unfair discrimination, particularly when non-traditional or behavioural data are involved.
That becomes increasingly relevant if insurers begin gathering richer information from metabolic-health programmes, digital coaching platforms, medication records or wearable devices.
Such data could help identify improvement that traditional underwriting misses.
They could also produce more granular segmentation between consumers.
The NAIC has separately highlighted continuing concerns around insurance data privacy as the volume of digital health and behavioural information available to insurers increases.
That means the success of metabolic-health insurance programmes cannot be measured in claims savings alone.
Governance matters too.
Policyholders need clarity about which data are collected, what they are used for, whether participation is voluntary, whether results can affect premiums or future coverage, and who has access to the information.
Prevention becomes an investment decision
The economic argument is nevertheless difficult for insurers to ignore.
In conventional healthcare financing, the organisation paying for prevention may not be the organisation that eventually captures the financial benefit. People change insurers, employers or healthcare systems.
Life and disability insurance can operate over much longer periods.
That potentially gives insurers a stronger incentive to invest today in preventing claims years later.
But only if the evidence holds.
Even speakers at the LIMRA session cautioned that insurers should establish whether metabolic-health programmes actually work before incorporating them into customer products. One proposal was to begin with employee programmes and evaluate outcomes before expanding externally.
That caution is probably the most important part of the discussion.
Obesity and metabolic disease clearly matter to insurance risk.
Interventions clearly can improve metabolic health.
What remains uncertain is whether insurers can combine those two truths into a scalable model that improves health, reduces claims and expands access without creating new forms of surveillance or exclusion.
If they can, the consequences could extend well beyond insurance.
The industry would no longer be paid only to understand who is likely to become sick. It would have a financial reason to help stop that sickness from happening.
